Letrozol-ratiopharm® 2,5 mg

Description

Indications

• early stages of estrogen receptor-expressing breast cancer in postmenopausal women – as adjuvant therapy;
• early-stage breast cancer in postmenopausal women after completion of standard adjuvant tamoxifen therapy – as extended adjuvant therapy;
• advanced hormone-dependent breast cancer in postmenopausal women – first-line therapy;
• advanced breast cancer in postmenopausal women (natural or artificially induced) who have received prior therapy with anti-estrogens.

Contraindications

• Endocrine status characteristic of the reproductive period;
• pregnancy;
• period of lactation (breastfeeding);
• childhood (efficacy and safety in children has not been established);
• hypersensitivity to the drug components.

The drug should be used with caution in lactase deficiency, lactase intolerance, glucose-galactose malabsorption.
There are no data on the use of Letrozole in patients with CK < 30 ml/min (before prescribing the drug to such patients, the ratio between the potential risk and expected effect of treatment should be carefully weighed).

Effect on the ability to drive transport and mechanisms

Some side effects of the drug, such as general weakness and dizziness, may affect the ability to perform potentially dangerous activities requiring increased concentration and quick psychomotor reactions. Therefore, patients should exercise caution when driving vehicles and operating machinery.